Vinnova Supports the Formation of Nordic CCRM Hub
The project is being coordinated by the recently formed not-for-profit CCRM Nordic AB and gathers engaged stakeholders to move the initiative forward.
Vinnova, Sweden’s Innovation Agency, granted funding for the establishment of a national cluster for commercialization of advanced therapies on May 24, 2023. The Centre for Commercialization of Regenerative Medicine (CCRM) Nordic will be located at GoCo Health Innovation City in Mölndal and will continue to focus on specialized infrastructure, focusing on advanced therapy medicinal product (ATMP) development.
According to the press release, the project is being coordinated by the recently formed not-for-profit CCRM Nordic AB and gathers engaged stakeholders to move the initiative forward.
“A lot is happening within the ATMP field both nationally and internationally, and I’m therefore very excited about the opportunity to manage the CCRM Nordic initiative from the establishment phase and onwards,” said Fredrik Wessberg, CCRM Nordic CEO, in a press release. “It is inspiring to see such great interest from developers and industry who are part of this consortium.”
ATMP is the European Medicines Agency classification of cell and gene therapy drugs, and tissue engineered drugs. Further, these products must be produced to good manufacturing practice standards and complete clinical trials before applying for market approval and becoming available to patients.
“I am delighted that Vinnova is committed to supporting this consortium to develop a CCRM hub for Sweden and its neighbors,” said Michael May, president and CEO of CCRM, Toronto, in a press release. “CCRM believes global collaboration is needed to maximize the health and economic benefits of ATMPs, and we have sought to partner with like-minded organizations with substantial activities and investments in regenerative medicine and cell and gene therapy. I am confident a CCRM Nordic will expedite the development of durable treatments for some of the world’s most debilitating and devastating diseases.”
Additionally, CCRM Nordic is going to be established as a new entity with national infrastructure for development, manufacturing, and commercialization of ATMPs. GoCo will be construct a purpose-built facility is expected to be operational in 2026 and will provide temporary offices and labs until then.
Source: CCRM Nordic
